David M. Leone

Dr. David M. Leone

orcid

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 January 2022 in Pediatric Cardiology
Verified
Journal Article
Closed access
PDF file
MHMichael He
Michael He
DLDavid M. Leone
David M. Leone
RFRichard Frye
Richard Frye
DFDina J. Ferdman
Dina J. Ferdman
VSVeronika Shabanova
Veronika Shabanova
RKRuchika Karnik
Ruchika Karnik

27 December 2024 in Children
Verified
Journal Article
Open access
PDF file
DLDavid M. Leone
David M. Leone
DODonnchadh O’sullivan
Donnchadh O’sullivan
KBKatia Bravo-Jaimes
Katia Bravo-Jaimes
Artificial intelligence (AI) is revolutionizing healthcare by offering innovative solutions for diagnosis, treatment, and patient management. Only recently has the field of pediatric cardiology begun to explore the use of deep learning methods to analyze electrocardiogram (ECG) data, aiming to enhance diagnostic accuracy, expedite workflows, and improve patient outcomes. This review examines the current state of AI-enhanced ECG interpretation in pediatric cardiology applications, drawing insights from adult AI-ECG research given the progress in this field. It describes a broad range of AI methodologies, investigates the unique challenges inherent in pediatric ECG analysis, reviews the current state of the literature in pediatric AI-ECG, and discusses potential future directions for research and clinical practice. While AI-ECG applications have demonstrated considerable promise, widespread clinical adoption necessitates further research, rigorous validation, and careful consideration of equity, ethical, legal, and practical challenges.

21 April 2026 in Circulation
Verified
Journal Article
Closed access
TGThomas M. Glenn
Thomas M. Glenn
NKNadine Kasparian
Nadine Kasparian
SAShahnawaz Amdani
Shahnawaz Amdani
DRDavid Renaud
David Renaud
MDMichael V. DiMaria
Michael V. DiMaria
AYAdel K. Younoszai
Adel K. Younoszai
BACKGROUND: Survival after Fontan palliation for single ventricle heart disease has improved substantially, yet the long-term trajectory remains poorly defined. The Fontan Outcomes Network, a learning health network of 38 congenital heart centers in the United States and Canada, was established to address this gap. We report baseline characteristics and early findings from the first 1121 participants enrolled in this prospective clinical registry. METHODS: We performed a cross-sectional analysis of individuals who had undergone Fontan palliation enrolled in the Fontan Outcomes Network from August 2022 through August 2024. Demographic, clinical, imaging, procedural, and medication data were analyzed descriptively, overall and by age group (<12, 12 to <18, and ≥18 years). RESULTS: A total of 1121 participants were enrolled (mean age, 16.3±10.2 years; 471 [42%] female). Hypoplastic left heart syndrome (n=431 [38.5%]) and right ventricular–dominant anatomy (n=615 [54.9%]) were the most common primary cardiac diagnoses, especially in younger age groups. Extracardiac conduit was the most frequent Fontan type (n=749 [66.8%]). Typical Fontan-related adverse events were noted in 59% of cases (n=662), including chylous pleural effusions (n=108 [9.6%]), Fontan thrombosis (n=79 [7.1%]), and nonperioperative stroke (n=73 [6.5%]). A history of arrhythmia was present in 41.3% of patients (n=463) overall, increasing with age. Acquired comorbidities were present in 57.5% of patients (n=645), including asthma (n=132 [12%]) and sleep apnea (n=103 [9%]), with burden increasing by age. Antithrombotic medication use was nearly universal. Use of other medications varied widely by age, and included β-blockers, angiotensin-converting enzyme inhibitors, and pulmonary vasodilators. A clinical diagnosis of an anxiety disorder was present in 34.1% of patients (n=382), including 48.1% of adults (n=194 of 403), and antidepressants were prescribed in 11.8% of patients (n=132), including 23.6% of adults (n=95 of 403), highlighting the mental health needs of this population. CONCLUSIONS: The Fontan Outcomes Network includes one of the largest prospective, multi-institutional data sets of patients with Fontan circulation. These initial findings demonstrate the potential for a collaborative learning health network to advance research and quality improvement for this rare disease population.

25 March 2022 in International Journal of Cardiology Congenital Heart Disease
Verified
Journal Article
Open access
DLDavid M. Leone
David M. Leone
HPHong-Jai Park
Hong-Jai Park
SUSerhan Unlu
Serhan Unlu
MGMichelle Gurvitz
Michelle Gurvitz
IKInsoo Kang
Insoo Kang
RERobert W. Elder
Robert W. Elder
T cells developed in the thymus play a key role in vaccine immunity. Thymectomy occurs during infant congenital heart surgery and results in an altered T cell distribution. We investigated if adults with congenital heart disease (ACHD) who underwent early thymectomy have a diminished response to influenza vaccination. Blood samples from ACHD with early thymectomy ≤ 1 year of age (ACHD-ET; n = 12), no thymectomy (ACHD-NT; n = 8), and healthy controls (HC; n = 14) were collected prior to and 4 weeks after influenza vaccination. Flow cytometric analysis of T cell subsets and vaccine-specific cytokine expressing CD4+ T cells as well as hemagglutination inhibition (HI) assays were completed. The mean age of the cohort was 34 ± 10.6 years and similar in all groups. The mean frequencies of naïve CD4+ and CD8+ T cells were lower in ACHD-ET than in HC (32.7% vs. 46.5%, p = 0.027 and 37.2% vs. 57.4%, p = 0.032, respectively). There was a rise in the frequency of memory CD4+ and CD8+ T cells in the ACHD-ET group. The ACHD-NT had no statistical difference from either group. The frequencies of influenza-specific memory CD4+ T cells expressing IFN-γ and TNF-α were increased after vaccination across all groups (p < 0.05). ACHD-ET have fewer naïve T cells, suggesting immunosenescence. Despite this, they show an adequate T Cell response to vaccination in young adulthood. Our findings support routine vaccination is effective in this population, but research into older ACHD is necessary.

24 August 2024 in International Journal of Cardiology Congenital Heart Disease
Verified
Journal Article
Open access
DLDavid M. Leone
David M. Leone
MMMatthew J. Magoon
Matthew J. Magoon
NANeha Arunkumar
Neha Arunkumar
LSLaurie A. Soine
Laurie A. Soine
EBElizabeth C. Bayley
Elizabeth C. Bayley
JBJonathan Buber
Jonathan Buber
Cardiopulmonary exercise testing (CPET) is used in evaluation of repaired tetralogy of Fallot (rTOF), particularly for pulmonary valve replacement need. Oxygen pulse (O2P) is the CPET surrogate for stroke volume and peripheral oxygen extraction. This study assessed O2P curve properties against non-invasive cardiac output monitoring (NICOM) and clinical testing. This cross-sectional study included 44 rTOF patients and 10 controls. Three new evaluations for O2P curve analysis during CPET were developed. Best fit early and late regression slopes of the O2P curve were used to calculate: 1) the early to late ratio, or "O2 pulse response ratio" (O2PRR); 2) the portion of exercise until slope inflection, or "flattening fraction" (FF); 3) the area under the O2P response curve, or "O2P curve area". rTOF patients (median age 35.2 (27.6-39.4); 61% female) had a lower VO2 max (23.4 vs 45.6 ml/kg/min; p < 0.001) and O2P max (11.5 vs 19.1 ml/beat; p < 0.001) compared to controls. Those with a FF occurring 50%. FF and O2P curve area significantly correlated with peak cardiac index, stroke volume, left and right ventricular ejection fraction, and right ventricular systolic pressure. CPET remains an integral part in the evaluation of rTOF. We introduce three non-invasive methods to assess exercise hemodynamics using the O2P curve data. These evaluations demonstrated significant correlations with stroke volume, cardiac output, and right ventricular pressure.